AbstractObjectivesWe aimed to compare the long‐term persistence between different tumor necrosis factor‐alpha inhibitors (TNFis) with immune‐mediated rheumatic diseases (IMRD). This study can potentially provide insights into the real‐world evidence regarding safety and effectiveness of TNFi treatment in a Chinese population.MethodsWe enrolled newly diagnosed IMRD patients in this active comparator, retrospective cohort study by using National Taiwan insurance claim datasets. The drug survivals of first‐line TNFi agents, including etanercept, golimumab, and adalimumab were compared. Propensity score matching was conducted to control the confounding effect from the observed covariates. The cumulative proportion of discontinuation was calculated over 5 years. The multiple‐variable regression and propensity score analysis was used for confounding adjustment.ResultsAfter propensity score matching, there were 2267 patients identified in each etanercept, golimumab, and adalimumab group. We observed the 5‐year cumulative proportion of discontinuation was 52.80%, 45.85%, and 56.86% in etanercept, golimumab, and adalimumab, respectively. Compared with golimumab, increase of 31% (95% CI: 20‐43) and 38% (95% CI: 26‐50) risk of discontinuation were observed in etanercept and adalimumab. The factors including female gender, increasing age, long hospital stays, without co‐medication with nonsteroidal anti‐inflammatory drugs or methotrexate were associated were discontinuation of first‐line TNFi treatment.ConclusionGolimumab had better drug survival than etanercept or adalimumab over 5 years of observation in Asian IMRD patients. Gender, age, longer hospital stays, concomitant use of disease‐modifying antirheumatic drugs were associated with survival with TNFis.